Calithera Biosciences (NASDAQ: CALA)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-08 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.650 | -1.590 | 1.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Calithera Biosciences (NASDAQ: CALA) through any online brokerage.
Other companies in Calithera Biosciences’s space includes: Biocept (NASDAQ:BIOC), Monopar Therapeutics (NASDAQ:MNPR), ABVC BioPharma (NASDAQ:ABVC), Biophytis (NASDAQ:BPTS) and Indaptus Therapeutics (NASDAQ:INDP).
The latest price target for Calithera Biosciences (NASDAQ: CALA) was reported by SVB Leerink on Tuesday, August 16, 2022. The analyst firm set a price target for 18.00 expecting CALA to rise to within 12 months (a possible 293.87% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Calithera Biosciences (NASDAQ: CALA) is $4.57 last updated Today at August 18, 2022, 3:35 PM UTC.
There are no upcoming dividends for Calithera Biosciences.
Calithera Biosciences’s Q3 earnings are confirmed for Tuesday, November 8, 2022.
There is no upcoming split for Calithera Biosciences.
Calithera Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.